Ethyl Maltol
C7H8O3 140.14
2-Ethyl-3-hydroxy-4-pyrone;
2-Ethyl-3-hydroxy-4H-pyran-4-one;
2-Ethyl pyromeconic acid
[4940-11-8].
+'&img=../../images/v35300/cas-4940-11-8.gif&casNumber=4940-11-8&usp=35&nf=30&chemicalStructureImage=true&ID='+parent.myID,600,500);)
C7H8O3 140.14
2-Ethyl-3-hydroxy-4-pyrone;
2-Ethyl-3-hydroxy-4H-pyran-4-one;
2-Ethyl pyromeconic acid
[4940-11-8].DEFINITION
Ethyl Maltol contains NLT 99.0% of C7H8O3, calculated on the anhydrous basis.
IDENTIFICATION
• A. Infrared Absorption 
197S
:
1:50 solution in chloroform
197S:
1:50 solution in chloroform
ASSAY
• Procedure
Standard solution:
10.0 µg/mL of USP Ethyl Maltol RS in 0.1 N hydrochloric acid
Sample solution:
10.0 µg/mL of Ethyl Maltol in 0.1 N hydrochloric acid
Instrumental conditions
Mode:
UV
Analytical wavelength:
276 nm
Cell:
1 cm
Blank:
0.1 N hydrochloric acid
Analysis
Samples:
Standard solution and Sample solution
Calculate the percentage of ethyl maltol (C7H8O3) in the portion of Ethyl Maltol taken:
Result = (AU/AS) × (CS/CU) × 100
| AU | = | = absorbance of the Sample solution |
| AS | = | = absorbance of the Standard solution |
| CS | = | = concentration of USP Ethyl Maltol RS in the Standard solution (µg/mL) |
| CU | = | = concentration of Ethyl Maltol in the Sample solution (µg/mL) |
Acceptance criteria:
NLT 99.0% on the anhydrous basis
IMPURITIES
• Residue on Ignition 281:
NMT 0.2% at 800
for 15 min
281:
NMT 0.2% at 800 for 15 min
SPECIFIC TESTS
• Water Determination, Method I 921:
NMT 0.5%
921:
NMT 0.5%
ADDITIONAL REQUIREMENTS
• Packaging and Storage:
Preserve in tight containers.
• USP Reference Standards 11
11
USP Ethyl Maltol RS 
') + '&img=../../images/v35300/cas-4940-11-8.gif',600,500);)
Auxiliary Information—
Please check for your question in the FAQs before contacting USP.
| Topic/Question | Contact | Expert Committee |
|---|---|---|
| Monograph | Robert H. Lafaver, M.S.
Scientific Liaison 1-301-816-8335 |
(EXC2010) Monographs - Excipients |
| Reference Standards | RS Technical Services 1-301-816-8129 rstech@usp.org |
USP35–NF30 Page 1794
Pharmacopeial Forum: Volume No. 34(5) Page 1224